Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMF and Daclizumab for New Onset Type 1 Diabetes
NCT00100178Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- May 2004
- Primary completion
- Apr 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of mycophenolate mofetil, daclizumab in type 1 diabetes mellitus (T1D), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started May 2004; status: completed.
02
Drugs
mycophenolate mofetildaclizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00100178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100178.